RxDoctor Payments Data

Mahyar Tahbaz, DO

Nephrology · Parkersburg, WVNPI 1770583031

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $2,135 of the $2,400 with a category attached, or 89.0%. It is spread thinly across 16 manufacturers, the largest accounting for just 21.4% — the pattern of someone who eats at a lot of different presentations.

$2,400in general payments, 2019–2025

Across 119 payments — averaging $20.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$513
  • Akebia Therapeutics Inc$356
  • Ardelyx, Inc.$271
  • Mallinckrodt Hospital Products Inc.$227
  • OPKO Pharmaceuticals, LLC$166
  • Amgen$162
  • plus $705 from 10 others

What the payments were for

  • Food & beverage$2,13589%
  • Education$26511%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,400 in reported general payments places this provider in the 70th percentile of 55 nephrology providers in West Virginia.

See all nephrology providers in West Virginia

Medicare billing

Part B allowed, 2024
$440,626
Medicare patients
667
Services billed
4,476

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XphozahTenapanor Hcl33$154,292
EliquisApixaban198$51,999
VelphoroSucroferric Oxyhydroxide20$40,561
FarxigaDapagliflozin Propanediol35$32,166
Sevelamer Carbonate85$18,777
XareltoRivaroxaban61$10,862
ArexvyRsvpref3 Antigen/As01e/Pf25$7,878
JardianceEmpagliflozin31$6,828
ProsolParenteral Amino Acid 20% No.136$5,168
Atorvastatin Calcium483$4,634
TradjentaLinagliptin11$4,425
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen217$3,957
Amlodipine Besylate437$3,520
Lisinopril456$3,493
Sertraline Hcl312$2,868

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$55$32,16635 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 55 nephrology providers in West Virginia.

Other nephrology in Parkersburg

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →